Study: Generics Could Cut Costs of HIV Treatment
January 15, 2013
HIV-infected patients may soon be able to switch from a branded one-pill combination of antiretroviral drugs to a less expensive protocol that combines generic and branded drugs. Current guidelines recommend HIV-infected people take the single-pill combination of efavirenz (Sustiva), emtricitabine (Emtriva), and tenofovir (Viread). The cheaper three-pill regimen would include a generic version of efavirenz, lamivudine (similar to emtricitabine), and Atripla. According to Rochelle Walensky, MD, the United States could see a savings of $920 million in the first year if every U.S. resident on antiretroviral therapy switched to the three-pill generic regimen.
[TheBody.com Editor's Note, 1/18/2013: The original version of this article incorrectly stated that Atripla was the brand name of tenofovir, rather than Viread. We have corrected the error on this page.]
01.14.2013; Michael Smith
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)